Fentanyl makeover: Core structural redesign could lead to safer pain medications
Source: Hacker News
[Image: Fentanyl molecular structures: traditional (left) and modified (right)]
*Fentanyl’s traditional molecular structure (left) works by acting on mu‑opioid receptors (top) to reduce pain and a protein called **beta‑arrestin‑2** (bottom) to cause respiratory depression, also known as slowed breathing.
Chemists at Scripps Research have developed a modified structure of the drug (right) that maintains its pain‑relieving signature while reducing respiratory depression.*
*Credit: Arran Stewart, Scripps Research*Fentanyl Makeover: Core Structural Redesign Could Lead to Safer Pain Medications
Modified molecule shows diminished respiratory depression—the leading cause of opioid‑overdose deaths—while retaining full pain‑blocking capability.
February 11, 2026
LA JOLLA, CA — Fentanyl is one of the most effective drugs for managing severe pain, yet it carries substantial risks of addiction and respiratory depression (the dangerous, sometimes fatal slowed breathing). These safety concerns have limited its use despite its potency. Meanwhile, the ease and low cost of manufacturing have enabled widespread illegal production, fueling an overdose epidemic that claimed more than 70,000 U.S. lives in 2023.
Now, chemists at Scripps Research have modified fentanyl’s molecular structure to develop a version that reduces respiratory depression while fully preserving its analgesic properties. The findings, published in ACS Medicinal Chemistry Letters on January 22, 2026, suggest that future modifications could yield next‑generation opioid therapies with less risk of addiction, overdose, and death. The paper was also highlighted as an ACS Editor’s Choice.
“For decades, the pharmaceutical industry has been constrained by the assumption that major structural changes to opioids would eliminate their analgesic properties,” says senior author Kim D. Janda, the Ely R. Callaway Jr. Professor of Chemistry at Scripps Research. “Our research has identified a different possibility—that fundamental structural redesign can preserve pain relief while improving safety.”
What the team did
Synthetic opioids like fentanyl occupy a complex position in medicine. Initially promoted as breakthrough medications with minimal addiction risk (claims that have proven tragically false), they remain essential for managing severe acute pain despite their dangers.
Janda’s group employed a medicinal‑chemistry strategy called “bioisosteric replacement.” Rather than tweaking small parts of the molecule, they replaced the central ring with an entirely different geometry: 2‑azaspiro[3.3]heptane, a spirocyclic scaffold that looks like linked paper chains.
“Rather than tweaking small parts of the molecule, we replaced the entire central structure with something that looks completely different in three‑dimensional space,” says first author Arran Stewart, research associate in the Janda laboratory.
Key findings
- Analgesic potency retained – The new core binds the μ‑opioid receptor with sufficient affinity to block pain, preserving the essential electrostatic “anchor” interaction while altering many peripheral contacts.
- No β‑arrestin recruitment – The compound showed no detectable activation of the β‑arrestin pathway, which is implicated in respiratory depression and other side effects.
- Reduced respiratory depression – Slowed breathing occurred only at very high doses and was transient, returning to baseline within 25–30 minutes.
- Short half‑life – The analog cleared quickly (t½ ≈ 27 min), offering a short‑acting profile useful in controlled medical settings.
Future directions
This redesign is part of Janda’s broader strategy to combat opioid overdose and adverse effects. The team plans to leverage the discovery to develop patent‑free opioid vaccines that train the immune system to neutralize fentanyl before it reaches the brain.
“Finding ways to preserve the analgesic properties of synthetic opioids without the perils of respiratory depression could help de‑risk the toxicity associated with synthetic opioid use while providing a new conduit for pain management,” says Janda.
Authors & Acknowledgments
Kim D. Janda (senior author) – Ely R. Callaway Jr. Professor of Chemistry, Scripps Research
Arran Stewart (first author) – Research Associate, Janda Laboratory
Lisa Eubanks – Scripps Research
Mingliang Lin – Scripps Research
This work was supported by the Shadek Family Foundation.
Categories: Chemistry
Keywords: Janda, Kim
Contact: press@scripps.edu
See More News
Share: